At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
03347 TIGERMED
Trading 12-30 11:11:18
42.400
-0.340
-0.80%
High43.320Low42.060Vol848.90K
Open43.040D1 Closing42.740Amplitude2.95%
Mkt Cap36.51BTradable Cap5.22BTotal Shares861.00M
T/O36.17MT/O Rate0.69%Tradable Shares123.12M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Delisted from Shenzhen 100, Market Cap Evaporates by 100 Billion: How Can Tigermed Overcome Its "Investment Dependence"?
Deep News  ·  12-25
Delisted from Shenzhen 100, Market Cap Evaporates by 100 Billion: How Can Tigermed Overcome Its "Investment Dependence"?
HK Stock Connect Shareholding Changes as of December 24
Stock News  ·  12-24
HK Stock Connect Shareholding Changes as of December 24
TIGERMED Removed from SZSE 100 Index After Losing Over 100 Billion in Market Value
Deep News  ·  12-18
TIGERMED Removed from SZSE 100 Index After Losing Over 100 Billion in Market Value
HK Stock Connect Shareholding Changes | December 8
Stock News  ·  12-08
HK Stock Connect Shareholding Changes | December 8
Xingquan Global Fund Reduces Stake in TIGERMED (03347) by 216,800 Shares at HK$37.7 per Share
Stock News  ·  12-04
Xingquan Global Fund Reduces Stake in TIGERMED (03347) by 216,800 Shares at HK$37.7 per Share
Hong Kong Stocks Surge: CRO Concept Stocks Rally in Afternoon Session with WUXI BIO (02269) Up Over 7%; Analysts Highlight Industry Consolidation Trend
Stock News  ·  12-04
Hong Kong Stocks Surge: CRO Concept Stocks Rally in Afternoon Session with WUXI BIO (02269) Up Over 7%; Analysts Highlight Industry Consolidation Trend
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
Tiger Newspress  ·  12-04
HK Movers | Biotech Stocks Rise. Ascletis up 9%; Antengene up over 5%; Remegen, Laekna, Akeso, Hua Medicine up About 4%
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Tiger Newspress  ·  12-03
HK Movers | Biotech Stocks Fall. Ascletis-B down 11%; Hua Medicine-B, Mabpharm-B down about 7%; Antengene-B down 5%; Ascentage-B down 4%.
Southbound Capital Flow Data (T+2) for Dec 2
Stock News  ·  12-02
Southbound Capital Flow Data (T+2) for Dec 2
JPMorgan Reduces Stake in TIGERMED (03347) by Approximately 831,200 Shares at Average Price of HK$39.82 per Share
Stock News  ·  12-01
JPMorgan Reduces Stake in TIGERMED (03347) by Approximately 831,200 Shares at Average Price of HK$39.82 per Share
JPMorgan Increases Stake in Tigermed (03347) by Approximately 501,500 Shares at HK$38.95 per Share
Stock News  ·  11-27
JPMorgan Increases Stake in Tigermed (03347) by Approximately 501,500 Shares at HK$38.95 per Share
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
Tiger Newspress  ·  11-26
HK Pharma Shares Gained. CSPC Pharma Up 7%; 3SBio Up 6%; Remegen Up 4%; Sino Biopharm, Junshi Bio And Hengrui Pharma Up 3%
HK Stocks Movement | CRO Sector Rebounds as Industry Performance Expected to Recover in H2; Morgan Stanley Sees Attractive Valuations in WuXi Group
Stock News  ·  11-24
HK Stocks Movement | CRO Sector Rebounds as Industry Performance Expected to Recover in H2; Morgan Stanley Sees Attractive Valuations in WuXi Group
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Tiger Newspress  ·  11-24
HK Movers｜Biotech Shares Gained. 3SBio And Hengrui Pharma Up 5%; Tigermed Up 3%; SKB Bio, JW Therap, Remegen And Wuxi XDC Up 2%
Hong Kong Stocks Movement | CRO Concept Stocks Plunge Collectively: GENSCRIPT BIO (01548) Drops Over 6%, PHARMARON (03759) Falls Over 4%
Stock News  ·  11-21
Hong Kong Stocks Movement | CRO Concept Stocks Plunge Collectively: GENSCRIPT BIO (01548) Drops Over 6%, PHARMARON (03759) Falls Over 4%
Gf Securities: Domestic R&D Investment Demand Recovery Highlights Left-Side Opportunities in Pharma Sector
Stock News  ·  11-20
Gf Securities: Domestic R&D Investment Demand Recovery Highlights Left-Side Opportunities in Pharma Sector
IPO Preview: "Stockpiling Monkeys" Drags Down Profits, Can Dingtai Pharma's "Water Seller" Story Hold Up?
Stock News  ·  11-20
IPO Preview: "Stockpiling Monkeys" Drags Down Profits, Can Dingtai Pharma's "Water Seller" Story Hold Up?
HK Stock Connect Shareholding Changes | Nov 13
Stock News  ·  11-13
HK Stock Connect Shareholding Changes | Nov 13
HK Stock Connect Shareholding Changes | November 12
Stock News  ·  11-12
HK Stock Connect Shareholding Changes | November 12
TIGERMED (03347) Rises Over 4% as Q3 Revenue Shows Significant Improvement with Double-Digit Growth in SMO New Orders
Stock News  ·  11-10
TIGERMED (03347) Rises Over 4% as Q3 Revenue Shows Significant Improvement with Double-Digit Growth in SMO New Orders

Introduction

Company Name.
TIGERMED
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hangzhou Tigermed Consulting Co Ltd is a China-based holding company engaged in providing clinical trial services for research and development of new drugs. The Company operates two segments. The Clinical Trial Solutions segment provides clinical trial operation services and medical translation services to biopharmaceutical and medical device companies and thus help them conduct clinical trials of innovative drugs, generic drugs and medical devices. The Clinical-Related and Laboratory Services segment is involved in provision of analytical services, such as data management and statistical analysis; logistics and execution support services, such as clinical trial site management; administrative assistance, such as patient recruitment; as well as consulting services. This segment also provides laboratory services for preclinical and clinical development stages through its subsidiary. The Company conducts its businesses in the domestic and overseas markets.
Issue price:
--